45 companies

Harmony Biosciences Holdings

Market Cap: US$2.1b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

HRMY

US$37.08

7D

-2.0%

1Y

-2.4%

Global Industrial

Market Cap: US$1.3b

Through its subsidiaries, operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in the United States and Canada.

GIC

US$32.48

7D

3.4%

1Y

37.2%

Applied Industrial Technologies

Market Cap: US$10.9b

Distributes industrial motion, power, control, and automation technology solutions in the United States, Canada, Mexico, Australia, New Zealand, Singapore, and Costa Rica.

AIT

US$282.45

7D

4.6%

1Y

7.0%

Pegasystems

Market Cap: US$6.8b

Develops, markets, licenses, hosts, and supports enterprise software in the United States, rest of the Americas, the United Kingdom, rest of Europe, the Middle East, Africa, and the Asia-Pacific.

PEGA

US$41.84

7D

-4.0%

1Y

-20.1%

Vita Coco Company

Market Cap: US$3.4b

Develops, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific.

COCO

US$58.41

7D

4.8%

1Y

48.3%

Pinterest

Market Cap: US$13.2b

Operates as a visual search and discovery platform in the United States, Canada, Europe, and internationally.

PINS

US$20.14

7D

-8.5%

1Y

-49.2%

ResMed

Market Cap: US$39.6b

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.

RMD

US$275.96

7D

8.3%

1Y

15.7%

Stride

Market Cap: US$3.7b

Provides proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally.

LRN

US$87.51

7D

1.1%

1Y

-37.8%

ACADIA Pharmaceuticals

Market Cap: US$4.0b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

ACAD

US$23.22

7D

-11.1%

1Y

23.0%

Page 2 of 2